Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Operating Expenses (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Operating Expenses data on record, last reported at $14.8 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 16.41% year-over-year to $14.8 million; the TTM value through Oct 2025 reached $56.3 million, up 3.52%, while the annual FY2025 figure was $52.4 million, 8.9% down from the prior year.
  • Operating Expenses reached $14.8 million in Q4 2025 per CSBR's latest filing, up from $14.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $15.6 million in Q2 2023 and bottomed at $9.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $13.4 million, with a median of $13.8 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: grew 25.77% in 2022, then fell 15.75% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $11.5 million in 2021, then grew by 23.87% to $14.3 million in 2022, then dropped by 5.23% to $13.5 million in 2023, then decreased by 5.7% to $12.8 million in 2024, then rose by 16.41% to $14.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $14.8 million in Q4 2025, $14.5 million in Q3 2025, and $14.4 million in Q2 2025.